August 7, 2006 -- Immunicon signed two agreements with AstraZeneca, one for biomarkers and the other for laboratory services; BioCryst has a Special Protocol Assessment for its cancer drug Fodosine; Corcept published positive results from a Phase II trial of Corlux, a drug for psychotic major depression;Taisho Pharma ended its partnership with Lilly on a drug for diabetes; Advanced Medical Optics sold 6 OTC eye-care products to Inyx; and Novelos Therapeutics received Fast Track designation for a lung cancer compound. The Centient Biotech 200™ fell 38 points to 3629.37, a loss of 1.03%. More details...
